Fulcrum Therapeutics Inc. (FULC) Tops Q4 EPS by 3c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.40), $0.03 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $870 thousand versus the consensus estimate of $552.72 thousand.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
• S&P 500 may pull back before midterms, but Citi says buy the dip